Search - tctmd.com

Displaying 161 - 180 of 273

Sort: Relevancy | Date

Presentation TCT 2016

Paravalvular Regurgitation - The Achilles Heel or Problem Solved: Latest Updates on the Assessment of Paravalvular Regurgitation (Aortic and Mitral)

Presenter: Carlos E. Ruiz, Ulrich Steinseifer, Rebecca T. Hahn

October 30, 2016

Presentation TCT 2016

Symptomatic High-Risk Aortic Regurgitation: Is TAVR A Viable Alternative?

Presenter: A. Pieter Kappetein, Allan Schwartz, Hendrik Treede

October 30, 2016

Presentation TCT 2016

Leaflet Thickening, Dysfunction, and Thrombosis: Clinical Perspectives- Are Problems Under-Reported? Are the Changes a Class Effect?

Presenter: Carlos E. Ruiz, Ulrich Steinseifer, Raj Makkar

October 30, 2016

Presentation TCT 2016

Leaflet Thickening, Dysfunction, and Thrombosis: Latest Recommendations by the ISO Cardiac Valves Committee

Presenter: Carlos E. Ruiz, Ulrich Steinseifer

October 30, 2016

Presentation TCT 2016

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Presenter: A. Pieter Kappetein, Allan Schwartz, Martin B. Leon

October 30, 2016

Presentation TCT 2016

TVA Medical Approach

Presenter: Mitchell W. Krucoff, Katherine Kumar

October 30, 2016

Presentation TCT 2016

Low-Flow Aortic Stenosis: Clinical Outcomes After TAVR

Presenter: A. Pieter Kappetein, Allan Schwartz, Howard C. Herrmann

October 30, 2016

Presentation TCT 2016

Low-Flow Aortic Stenosis: Pathophysiology, Syndrome Classification, and Prognosis

Presenter: A. Pieter Kappetein, Allan Schwartz, Philippe Pibarot

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Early Insights from Industry

Presenter: Charles J. Davidson, Nicole Ibrahim, Dan Mans

October 30, 2016

Presentation TCT 2016

Transcatheter Valve-in-Valve Therapy: Clinical and Technical Pearls

Presenter: A. Pieter Kappetein, Allan Schwartz, Vinayak Bapat

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Presenter: A. Pieter Kappetein, Allan Schwartz, Danny Dvir

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Sara Takahashi

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger

October 30, 2016

Presentation TCT 2016

TAVR Outcomes and Technical Pearls in Bicuspid Aortic Stenosis (With Case Examples)

Presenter: A. Pieter Kappetein, Allan Schwartz, Mathew Williams

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Rachel Neubrander

October 30, 2016

Presentation TCT 2016

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

Presenter: A. Pieter Kappetein, Allan Schwartz, Lars Sondergaard

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Kenneth Stein, MD

October 30, 2016

Presentation TCT 2016

Lessons Learned from Early FIH/EFS Trials: Transcatheter Pulmonary Valve Replacement

Presenter: John G. Webb, Ajit Yoganathan, John P. Cheatham

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, David J. Cohen

October 30, 2016

Advertisement

Paravalvular Regurgitation - The Achilles Heel or Problem Solved: Latest Updates on the Assessment of Paravalvular Regurgitation (Aortic and Mitral)

Symptomatic High-Risk Aortic Regurgitation: Is TAVR A Viable Alternative?

Leaflet Thickening, Dysfunction, and Thrombosis: Clinical Perspectives- Are Problems Under-Reported? Are the Changes a Class Effect?

Leaflet Thickening, Dysfunction, and Thrombosis: Latest Recommendations by the ISO Cardiac Valves Committee

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

TVA Medical Approach

Low-Flow Aortic Stenosis: Clinical Outcomes After TAVR

Low-Flow Aortic Stenosis: Pathophysiology, Syndrome Classification, and Prognosis

TMVR Clinical Trial Design: Early Insights from Industry

Transcatheter Valve-in-Valve Therapy: Clinical and Technical Pearls

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

FDA Perspectives

TAVR Outcomes and Technical Pearls in Bicuspid Aortic Stenosis (With Case Examples)

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Lessons Learned from Early FIH/EFS Trials: Transcatheter Pulmonary Valve Replacement

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content